The breast-thyroid cancer link: A systematic review and meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 2, 2016, Pages 231-238

  Nielsen, Sarah M ^a   White, Michael G ^b   Hong, Susan ^a   Aschebrook Kilfoy, Briseis ^a   Kaplan, Edwin L ^b   Angelos, Peter ^b   Kulkarni, Swati A ^c   Olopade, Olufunmilayo I ^a   Grogan, Raymon H ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Endocrine Surgery   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCOPUS; SYSTEMATIC REVIEW; THYROID CANCER; BREAST NEOPLASMS; COHORT ANALYSIS; FEMALE; MALE; MORTALITY; THYROID NEOPLASMS;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MALE; THYROID NEOPLASMS;

EID: 84957806067     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0833     Document Type: Review

References (88)

1. Travis LB, Demark Waefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289-301.
2. Li CI, Rossing MA, Voigt LF, Daling JR. Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States). Cancer Causes Control 2000;11:805-11.
3. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005;117:281-8.
4. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 2006;91:1819-25.
5. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007;17:1277-88.
6. Mellemkjaer L, Christensen J, Frederiksen K, Pukkala E, Weiderpass E, Bray F, et al. Risk of primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers Prev 2011;20:1784-92.
7. Lal G, Groff M, Howe JR, Weigel RJ, Sugg SL, Lynch CF. Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol 2012;19:1887-96.
8. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973- 2002. Cancer Causes Control 2009;20:525-31.
9. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-22.
10. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013.
11. Schenker JG, Levinsky R, OhelG. Multiple primarymalignant neoplasms in breast cancer patients in Israel. Cancer 1984;54:145-50.
12. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:99-112.
13. Teppo L, Pukkala E, Saxen E. Multiple cancer-an epidemiologic exercise in Finland. J Natl Cancer Inst 1985;75:207-17.
14. Murakami R, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following female breast cancer in Osaka, Japan-a population-based cohort study. Jpn J Clin Oncol 1987;17:293-302.
15. Doherty MA, Rodger A, Langlands AO, Kerr GR. Multiple primary tumours in patients treated with radiotherapy for breast cancer. Radiother Oncol 1993;26:125-31.
16. Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997;8:764-70.
17. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 2000;61:183-95.
18. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 2001;84:435-40.
19. Huang J, Walker R, Groome PG, Shelley W, Mackillop WJ. Risk of thyroid carcinoma in a female population after radiotherapy for breast carcinoma. Cancer 2001;92:1411-8.
20. Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 2001;92:1-8.
21. Levi F, Te VC, Randimbison L, La Vecchia C. Cancer risk in women with previous breast cancer. Ann Oncol 2003;14:71-3.
22. Sadetzki S, Calderon-Margalit R, Peretz C, Novikov I, Barchana M, Papa MZ. Second primary breast and thyroid cancers (Israel). Cancer Causes Control 2003;14:367-75.
23. Soerjomataram I, Louwman WJ, de Vries E, Lemmens VE, Klokman WJ, Coebergh JW. Primary malignancy after primary female breast cancer in the Southof theNetherlands, 1972-2001. BreastCancer Res Treat 2005;93:91-5.
24. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;118: 2285-92.
25. Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer 2006;94:1745-50.
26. Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A, et al. Second malignancies after breast cancer: The impact of different treatment modalities. Br J Cancer 2008;98:870-4.
27. Lee KD, Chen SC, Chan CH, Lu CH, Chen CC, Lin JT, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev 2008;17:2647-55.
28. Molina-Montes E, Pollan M, Payer T, Molina E, Davila-Arias C, Sanchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol 2013;130: 340-5.
29. Ron E, Curtis R, Hoffman DA, Flannery JT. Multiple primary breast and thyroid cancer. Br J Cancer 1984;49:87-92.
30. Osterlind A, Olsen JH, Lynge E, Ewertz M. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80. Natl Cancer Inst Monogr 1985;68: 361-88.
31. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986;59:45-51.
32. Johns ME, Shikhani AH, Kashima HK, Matanoski GM. Multiple primary neoplasms in patients with salivary gland or thyroid gland tumors. Laryngoscope 1986;96:718-21.
33. Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991;64:159-63.
34. Glanzmann C. Subsequent malignancies in patients treated with 131- iodine for thyroid cancer. Strahlenther Onkol 1992;168:337-43.
35. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995;36:21-7.
36. Edhemovic I, Volk N, Auersperg M. Second primary cancers following thyroid cancer in Slovenia. A population-based cohort study. Eur J Cancer 1998;34:1813-4.
37. Hemminki K, Jiang Y. Second primary neoplasms after 19281 endocrine gland tumours: aetiological links? Eur J Cancer 2001;37:1886-94.
38. Adjadj E, Rubino C, Shamsaldim A, Le MG, Schlumberger M, de Vathaire F. The risk of multiple primary breast and thyroid carcinomas. Cancer 2003;98:1309-17.
39. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.
40. Berthe E, Henry-AmarM, Michels JJ, Rame JP, Berthet P, Babin E, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004;31:685-91.
41. Verkooijen RB, Smit JW, Romijn JA, Stokkel MP. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 2006;155:801-6.
42. Consorti F, Di Tanna G, Milazzo F, Antonaci A. Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer. World J Surg Oncol 2011;9:88.
43. Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid 2013;23:575-82.
44. Lu CH, Lee KD, Chen PT, Chen CC, Kuan FC, Huang CE, et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur J Endocrinol 2013;169:577-85.
45. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"-screening and overdiagnosis. N Engl J Med 2014;371:1765-7.
46. Zhang Y, Chen Y, Huang H, Sandler J, Dai M, Ma S, et al. Diagnostic radiography exposure increases the risk for thyroid microcarcinoma: a population-based case-control study. Eur J Cancer Prev 2015;24: 439-46.
47. O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials. PLoS ONE 2014;9:e106880.
48. Uppal A, White MG, Nagar S, Aschebrook-Kilfoy B, Chang PJ, Angelos P, et al. Benign and malignant thyroid incidentalomas are rare in routine clinical practice: a review of 97, 908 imaging studies. Cancer Epidemiol Biomarkers Prev 2015;24:1327-31.
49. Yane K, Kitahori Y, Konishi N, Okaichi K, Ohnishi T, Miyahara H, et al. Expression of the estrogen receptor in human thyroid neoplasms. Cancer Lett 1994;84:59-66.
50. Mori M, Naito M, Watanabe H, Takeichi N, Dohi K, Ito A. Effects of sex difference, gonadectomy, and estrogen on N-methyl-N-nitrosourea induced rat thyroid tumors. Cancer Res 1990;50:7662-7.
51. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010;20:33-41.
52. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008;93:809-14.
53. Negri E, Ron E, Franceschi S, Dal Maso L, Mark SD, Preston-Martin S, et al. A pooled analysis of case-control studies of thyroid cancer. I. Methods. Cancer Causes Control 1999;10:131-42.
54. Silva JM, Dominguez G, Gonzalez-Sancho JM, Garcia JM, Silva J, Garcia- Andrade C, et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 2002;21:4307-16.
55. Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 2008;109: 57-66.
56. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, et al. Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol 2010;171:242-52.
57. Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011;20:464-72.
58. DePergola GSF.Obesity as amajor risk factor for cancer. J Obes 2013. Epub 2013 Aug 29.
59. Han JM, Kim TY, Jeon MJ, Yim JH, Kim WG, Song DE, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013;168:879-86.
60. Sanchez L, Lana A, Hidalgo A, Rodriguez JM, Del Valle Mdel O, Cueto A, et al. Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev 2008;17:406-13.
61. Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS. Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol 2013;40:676-89.
62. Duffy BJ Jr, Fitzgerald PJ. Cancer of the thyroid in children: a report of 28 cases. J Clin Endocrinol Metab 1950;10:1296-308.
63. Kaplan EL, Mhoon D, Kaplan SP, Angelos P. Radiation-induced thyroid cancer: The Chicago experience. Surgery 2009;146:979-85.
64. GreenDM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000;18:1492-9.
65. Schellong G, Riepenhausen M, Ehlert K, Bramswig J, Dorffel WGerman Working Group on the Long-Term Sequelae of Hodgkin's D, et al. Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence-an observational study with up to 33-year follow-up. Dtsch Arztebl Int 2014;111:3-9.
66. Land CE, Boice JD Jr, Shore RE, Norman JE, Tokunaga M. Breast cancer risk from low-dose exposures to ionizing radiation: results of parallel analysis of three exposed populations of women. J Natl Cancer Inst 1980;65:353-76.
67. Cardis E, Hatch M. The Chernobyl accident-an epidemiological perspective. Clin Oncol (R Coll Radiol) 2011;23:251-60.
68. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003;30:740-8.
69. Hallquist A, Hardell L, Lofroth PO. External radiotherapy prior to thyroid cancer: a case-control study. Int J Radiat Oncol Biol Phys 1993;27:1085-9.
70. Yu GP, Schantz SP, Neugut AI, Zhang ZF. Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer Causes Control 2006;17:411-20.
71. Kim SS, Kim SJ, Bae YT, Lee JY, Kim BH, Kim YK, et al. Factors associated with the development of new onset diffuse thyroid F18-fluorodeoxyglucose uptake after treatment of breast cancer in patients without a history of thyroid disease or thyroid dysfunction. Thyroid 2012;22:53-8.
72. Kikuchi S, Perrier ND, Ituarte P, Siperstein AE, Duh QY, Clark OH. Latency period of thyroid neoplasia after radiation exposure. Ann Surg 2004;239: 536-43.
73. de Vathaire F. The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2008;4:180-1.
74. Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 1994;21:604-8.
75. de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997;75:734-9.
76. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primarymalignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19: 451-7.
77. Hall P, Holm LE, Lundell G, Ruden BI. Tumors after radiotherapy for thyroid cancer. A case-control study within a cohort of thyroid cancer patients. Acta Oncol 1992;31:403-7.
78. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, et al. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 2006;238:42-52.
79. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-15.
80. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994;86:1600-8.
81. Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 2014;32:1818-24.
82. Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowdenlike syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet 2012;21:300-10.
83. Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2010;31: 41-51.
84. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA 2010;304:2724-31.
85. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011;96:E2063-71.
86. Force USPST. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716-26.
87. McTiernan A, Weiss NS, Daling JR. Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer. Cancer Res 1987;47:292-5.
88. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92:225-31.